BriaCell Therapeutics Corp. (BCTX)
NASDAQ: BCTX · Real-Time Price · USD
0.561
-0.024 (-4.12%)
At close: Dec 20, 2024, 4:00 PM
0.580
+0.019 (3.39%)
After-hours: Dec 20, 2024, 7:28 PM EST
BriaCell Therapeutics Income Statement
Financials in millions USD. Fiscal year is August - July.
Millions USD. Fiscal year is Aug - Jul.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Oct '24 Oct 31, 2024 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 | Jul '20 Jul 31, 2020 |
| Selling, General & Admin | 6.52 | 6.65 | 8.51 | 7.58 | 4.96 | 1.54 | |
| Research & Development | 23.46 | 26.68 | 14.76 | 7.71 | 2.02 | 2.4 | |
| Operating Expenses | 29.98 | 33.33 | 23.27 | 15.29 | 6.98 | 3.94 | |
| Operating Income | -29.98 | -33.33 | -23.27 | -15.29 | -6.98 | -3.94 | |
| Interest Expense | - | - | - | -0 | -0.08 | -0.03 | |
| Interest & Investment Income | 0.11 | 0.29 | 0.89 | 0.14 | 0 | - | |
| Earnings From Equity Investments | -0.18 | -0.11 | - | - | - | - | |
| Currency Exchange Gain (Loss) | -0.02 | -0.03 | -0.04 | -0.03 | -2.18 | -0.01 | |
| Other Non Operating Income (Expenses) | 13.34 | 28.24 | 2.12 | -11.65 | -4.45 | 0.02 | |
| EBT Excluding Unusual Items | -16.72 | -4.93 | -20.3 | -26.84 | -13.67 | -3.96 | |
| Other Unusual Items | - | - | - | - | -0.14 | -0.06 | |
| Pretax Income | -16.72 | -4.93 | -20.3 | -26.84 | -13.82 | -4.02 | |
| Earnings From Continuing Operations | -16.72 | -4.93 | -20.3 | -26.84 | -13.82 | -4.02 | |
| Minority Interest in Earnings | 0.12 | 0.14 | - | - | - | - | |
| Net Income | -16.6 | -4.79 | -20.3 | -26.84 | -13.82 | -4.02 | |
| Net Income to Common | -16.6 | -4.79 | -20.3 | -26.84 | -13.82 | -4.02 | |
| Shares Outstanding (Basic) | 19 | 16 | 16 | 15 | 5 | 1 | |
| Shares Outstanding (Diluted) | 19 | 16 | 16 | 15 | 5 | 1 | |
| Shares Change (YoY) | 21.51% | 5.35% | 0.81% | 242.82% | 533.09% | 23.16% | |
| EPS (Basic) | -0.87 | -0.29 | -1.30 | -1.73 | -3.06 | -5.64 | |
| EPS (Diluted) | -0.87 | -0.29 | -1.30 | -1.73 | -3.06 | -5.64 | |
| Free Cash Flow | -23.93 | -24.58 | -23.74 | -12.48 | -7.75 | -1.27 | |
| Free Cash Flow Per Share | -1.25 | -1.49 | -1.52 | -0.81 | -1.71 | -1.77 | |
| EBITDA | -29.87 | -33.25 | -23.26 | -15.27 | -6.96 | -3.92 | |
| D&A For EBITDA | 0.11 | 0.08 | 0.02 | 0.02 | 0.02 | 0.02 | |
| EBIT | -29.98 | -33.33 | -23.27 | -15.29 | -6.98 | -3.94 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.